SUNFLOWER(SZ:300111) Sou Hu Cai Jing·2026-01-17 12:38Core Viewpoint - The company Sunflower (300111.SZ) is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure, leading to the termination of its restructuring plan and a significant drop in stock price, causing substantial losses for investors [2][5][10]. Group 1: Investigation and Legal Actions - On January 14, 2026, the CSRC issued a notice of investigation against Sunflower due to suspected violations of information disclosure laws [7]. - The investigation is based on the company's restructuring plan announced on September 22, 2025, which was found to contain misleading statements regarding the actual production capacity and business model of the restructuring targets [2][10]. - The company has stated it will cooperate with the CSRC's investigation and maintain normal business operations during this period [7]. Group 2: Stock Market Impact - Following the announcement of the investigation, Sunflower's stock price fell by 10% on January 14, 2026, and continued to decline, hitting a 20% limit down on January 15, 2026, and closing down 17.94% on January 16, 2026 [5]. - The stock had previously experienced a surge, with three consecutive trading days of gains before the investigation was announced [10]. Group 3: Restructuring Plan and Business Focus - The restructuring plan aimed to position Sunflower in the semiconductor industry, leveraging its factories in Zhangzhou and Lanzhou, which were later revealed to lack actual production capacity [10]. - Sunflower's main business focus remains in the pharmaceutical sector, specifically in the research, manufacturing, and sales of drugs for infections, cardiovascular issues, and digestive system disorders [11].